EHA2026 abstract submission

You can submit your abstract as early as January 1, 2026.

All abstracts for EHA2026 will be peer reviewed, and accepted abstracts will be released online.

Abstracts will be available online from May 12, 2026 (15:30 CEST).

The Abstract Book will become available via the Congress platform and via HemaSphere (the official journal of EHA).

• January 1, 2026: Abstract submission and travel/participation grant applications open 
• March 1, 2026 (23:59 CET): Deadline for abstract submission and travel/participation grant application
• April 24, 2026: Deadline for the announcement of the allocation of abstracts to authors
• May 1, 2026 (23:59 CEST): Withdrawal deadline (regular abstracts)
• April 30, 2026: Late-breaking abstract submission opens  
• May 7, 2026 (09:00 CEST): Deadline for late-breaking abstract submission
• May 12, 2026 (15:30 CEST): Accepted abstracts available online
• May 22, 2026: Deadline for the announcement of the allocation of late-breaking abstracts to authors
• June 2, 2026 (15:30 CEST): Accepted late-breaking abstracts available online  

1. Acute lymphoblastic leukemia – Biology & translational research 
2. Acute lymphoblastic leukemia – Clinical 
3. Acute myeloid leukemia – Biology & translational research 
4. Acute myeloid leukemia – Clinical 
5. Chronic lymphocytic leukemia and related disorders – Biology & translational research 
6. Chronic lymphocytic leukemia and related disorders – Clinical 
7. Chronic myeloid leukemia – Biology & translational research 
8. Chronic myeloid leukemia – Clinical 
9. Myelodysplastic syndromes – Biology & translational research 
10. Myelodysplastic syndromes – Clinical 
11. Bone marrow failure syndromes incl. PNH – Biology & translational research 
12. Bone marrow failure syndromes incl. PNH – Clinical 
13. Myeloma and other monoclonal gammopathies – Biology & translational research 
14. Myeloma and other monoclonal gammopathies – Clinical 
15. Myeloproliferative neoplasms – Biology & translational research 
16. Myeloproliferative neoplasms – Clinical 
17. Hodgkin lymphoma – Clinical 
18. Indolent and mantle-cell non-Hodgkin lymphoma – Clinical 
19. Large B Cell Lymphomas – Clinical   
20. Other aggressive lymphomas  
21. Lymphoma biology & translational research 
22. Stem cell transplantation – Experimental 
23. Stem cell transplantation – Clinical 
24. Hematopoiesis, stem cells and microenvironment 
25. Gene therapy, cellular immunotherapy and vaccination – Biology & translational research 
26. Gene therapy, cellular immunotherapy and vaccination – Clinical 
27. Sickle cell disease 
28. Thalassemias 
29. Enzymopathies, membranopathies and other red blood cell disorders  
30. Iron metabolism, deficiency and overload 
31. Infections in hematology (incl. supportive care/therapy) 
32. Transfusion medicine  
33. Platelet disorders 
34. Bleeding disorders (congenital and acquired) 
35. Thrombosis and vascular biology 
36. Quality of life, ethics, supportive and palliative care 
37. Health economics 
38. Novel technologies, techniques and digital analytical tools in hematology